Preliminary Evaluation of the Diagnostic Usefulness of Uroplakin 2 with an Assessment of the Antioxidant Potential of Patients with Bladder Cancer

et al. 2020

Preprint

This study attempts to identify and validate biomarkers that can be used to monitor recurrence after LUAD surgery. We downloaded lung adenocarcinoma data from the TCGA database and selected postoperative recurrence samples, and then performed WGCNA analysis to find key co-expression gene modules. Enrichment analysis of key gene modules was also performed using the DAVID database. Finally, we performed a survival analysis of the most interesting biomarker UPK2 obtained from the TCGA analysis in the Oncomine database and evaluated its impact on prognosis. Using WGCNA analysis, we obtained 39 gene modules, of which the purple module was most associated with recurrence. Among them, UPK2, KLHDC3, GALR2 and TYRP1 occupied a central position in the co-expression network which were also significantly correlated with the survival of patients. We collected 132 blood samples from patients with early-stage lung adenocarcinoma who were tested the expression level of free UPK2 in the plasma. The expression of UPK2 relative to GADPH in non-relapsed patients was 0.1623, and in relapsed patients, it was 0.2763. ROC was used to evaluate the effectiveness of free UPK2 mRNA in the blood for monitoring postoperative recurrence, with an AUC of 0.767 and a 95% confidence interval of 0.675–0.858. At the same time, patients with high expression of free UPK2 mRNA had significantly poorer survival than those with low expression of UPK2. The expression level of free UPK2 mRNA in plasma has the potential as an indicator of postoperative recurrence in patients with early LUAD.

mentioning

confidence: 52%

Potential for The Blood-Biomarker Cell Free UPK2 RNA to Detect Recurrence During Monitoring After Surgical Resection of Adenocarcinoma of the Lung

et al. 2020

Preprint

“…Li et al (41) reported that UPK2 is expressed in 63% of plasma cell samples, which is significantly higher than UPK3 expression (6%), and further suggested that UPK2 is a valuable marker and should be included in immunohistochemical markers to facilitate the differential diagnosis of tumors with plasmacytoid features. Furthermore, Matuszewski et al (42) demonstrated that the concentration of UPK2 in urine decreased with the progression of bladder cancer, which further confirms the diagnostic value of UPK2 concentration in plasma and urine for bladder cancer. Tian et al (43) assessed UPK2 expression via bladder tissue microarray and reported that UPK2 is highly specific (100%) and can be used as a marker to identify urothelial lineage tumors and to help distinguish between bladder and prostate cancers, or (44) demonstrated that the positive rate of UPK2, GATA3 and p40 antibody combined testing was 94.2% (97/103) in invasive urothelial carcinoma, indicating that combination of these three antibodies has a high sensitivity to the differential diagnosis of invasive urothelial carcinoma.…”

Section: Discussionmentioning

confidence: 74%

Potential of the cell‑free blood‑based biomarker uroplakin 2 RNA to detect recurrence after surgical resection of lung adenocarcinoma

et al. 2021

Oncol Lett

Lung adenocarcinoma (LUAD) is the most common subtype of lung cancer, and ~30% of patients with LUAD develop cancer recurrence after surgery. The present study aimed to identify and validate biomarkers that may be used to monitor recurrence following LUAD surgery. Data from patients with LUAD were downloaded from The Cancer Genome Atlas database and postoperative recurrence samples were selected. Subsequently, weighted gene co-expression network analysis (WGCNA) was subsequently performed to identify key co-expression gene modules. Additionally, enrichment analysis of the key gene modules was performed using the Database for Annotation, Visualization and Integrated Discovery. Furthermore, survival analysis was performed on the most notable biomarker, uroplakin 2 (UPK2), which was downloaded from the Oncomine database, and its effect on prognosis was assessed. WGCNA identified 39 gene modules, of which one was most associated with recurrence. Among them, UPK2, kelch domain containing 3, galanin receptor 2 and tyrosinase-related protein 1 served a central role in the co-expression network and were significantly associated with the survival of patients. A total of 132 blood samples were collected from patients with LUAD with free UPK2 in the plasma. The expression levels of UPK2 relative to GADPH were 0.1623 and 0.2763 in non-relapsed and relapsed patients, respectively. Receiver operating characteristic curve analysis was used to detect free UPK2 mRNA in the blood in order to monitor postoperative recurrence, resulting in an area under the curve of 0.767 and a 95% CI of 0.675-0.858. Patients with high free UPK2 mRNA expression had unfavorable survival outcomes compared with those with low UPK2 expression. Therefore, free UPK2 mRNA expression in the plasma may have the potential to act as an indicator of postoperative recurrence in patients with early stage LUAD.

“…Li et al (30) have found that UPK2 is expressed in 63% of plasma cell samples, signi cantly higher than UPK3 (6%), and they further indicate that UPK2 is a valuable marker and should be included in immunohistochemical markers to facilitate the differential diagnosis of tumors with plasmacytoid features. Further studies by Matuszewski et al (31) have found that with the development of bladder cancer, the concentration of UPK2 in the urine is decreased, which further con rms the diagnostic value of UPK2 concentration in plasma and urine for bladder cancer. Based on clinical diagnostic needs, Tian et al (32) have evaluated the expression of UPK2 by bladder tissue microarray and nd that UPK2 is highly speci c (100%).…”

Section: Discussionmentioning

confidence: 75%

Potential for the blood- biomarker cell free UPK2 RNA to detect recurrence during monitoring after surgical resection of adenocarcinoma of the lung

et al. 2020

Preprint

Background: Lung cancer is one of the most common malignant tumors in the world. Non-small-cell lung cancer (NSCLC) accounting for top of all diagnosed lung cancers. Lung adenocarcinoma(LUAD) is the most common subtype in NSCLC. This study attempts to identify and validate biomarkers that can be used to monitor recurrence after LUAD surgery. Methods: In this research, we downloaded lung adenocarcinoma data from the TCGA database and selected postoperative recurrence samples, and then performed WGCNA analysis to find key co-expression gene modules. Enrichment analysis of key gene modules was also performed using the DAVID database. Finally, we performed a survival analysis of the most interesting biomarker UPK2 obtained from the TCGA analysis in the Oncomine database and evaluated its impact on prognosis. We collected 132 blood samples from patients with early-stage lung adenocarcinoma who were tested the expression level of free mRNA in the plasma.Results: The results revealed that UPK2, KLHDC3, GALR2 and TYRP1 occupied a central position in the co-expression network which were also significantly correlated with the survival of patients. The expression level of free UPK2 in the plasma relative to GADPH in non-relapsed patients was 0.1623, and in relapsed patients, it was 0.2763. ROC was used to evaluate the effectiveness of free UPK2 mRNA in the blood for monitoring postoperative recurrence, with an AUC of 0.767 and a 95% confidence interval of 0.675-0.858. At the same time, patients with high expression of free UPK2 mRNA had significantly poorer survival than those with low expression of UPK2. Conclusions: The expression level of free UPK2 mRNA in plasma has the potential as an indicator of postoperative recurrence in patients with early LUAD. This may have guiding significance for the subsequent clinical treatment of patients.